<DOC>
	<DOCNO>NCT01427114</DOCNO>
	<brief_summary>The purpose study determine efficient combination rituximab , cyclophosphamide , vincristine , prednisolone ( R-CVP ) treatment stage I II non-conjunctival ocular adnexal MALT lymphoma ( OAML ) .</brief_summary>
	<brief_title>R-CVP Treatment Non-conjunctival Ocular Adnexal MALT Lymphoma ( OAML )</brief_title>
	<detailed_description>The treatment stage I II OAML mainly compose radiotherapy chemotherapy include cyclophosphamide , vincristine , prednisolone ( CVP ) show acceptable response rate compare radiotherapy . However , radiotherapy disease cause many complication eye . This clinical trial design examine efficacy R-CVP combination therapy first-line treatment stage I II non-conjunctival OAML aim avoid radiation hazard increase efficacy CVP chemotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Histologically confirm OAML Nonconjunctival bilateral conjunctival ( TNMbased , T1N0M0 bT1N0M0 ) , Ann Arbor stage I II OAML Previously untreated Age ≥18 year Performance status : ECOG 02 Adequate hematological function : hemoglobin ≥9 g/dL , , absolute neutrophil count ( ANC ) ≥1,500/μL , platelet count ≥100,000/μL , unless abnormality due bone marrow involvement lymphoma Adequate liver function test : i. Transaminase ( AST/ALT ) &lt; 3 time upper normal value ii . Bilirubin &lt; 2 time upper normal value Adequate renal function : serum creatinine level &lt; 2 mg/dL ( 177 μmol/L ) Life expectancy ≥ 6 month A negative serum urine pregnancy test treatment must available premenopausal woman woman &lt; 2 year onset menopause . Informed consent NHL subtypes OAML Primary conjunctival OAML , unilateral involve ( T1N0M0 ) Ann Arbor stage III IV CNS involvement lymphoma evidence spinal cord compression . Brain CT/MRI mandatory ( within 4 week ) clinical suspicion CNS involvement lymphoma Pregnant lactate woman , woman childbearing potential use adequate contraception Inadequate liver function test : i. Transaminase ( AST/ALT ) ≥3 time upper normal value ii . Bilirubin ≥2 time upper normal value Inadequate renal function : i. serum creatinine level &lt; 2 mg/dL ( 177 μmol/L ) Other serious illness medical condition i. Unstable cardiac disease despite treatment ; myocardial infarction within 6 month prior study entry ii . History significant neurological psychiatric disorder include dementia seizure Active uncontrolled infection ( HIV , hepatitis B , Hepatitis C , active Tuberculosis , active bacterial , active fungal infection ) Any malignancy within past 5 year except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri Known hypersensitivity study drug ingredient ( i.e. , hypersensitivity Polysorbate 20 , CHO cell product , recombinant human antibody ) Concomitant administration experimental drug investigation concomitant chemotherapy , hormonal therapy , immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>extranodal marginal zone lymphoma</keyword>
	<keyword>ocular adnexal lymphoma</keyword>
	<keyword>mucosa associate lymphoid tissue</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>vincristine</keyword>
	<keyword>prednisolone</keyword>
</DOC>